Coated bone grafts are provided as well as methods of use thereof and methods of making. In accordance with the instant invention, methods of preparing a coated bone graft (e.g., bone allograft) are provided. In certain embodiments, the method comprises electrospraying a composition comprising a polymer and, optionally, an agent, particularly a therapeutic agent, onto the surface of the bone graft. Therapeutic agents include, without limitation: bone stimulating agents, anti-fibrotic agents, antimicrobials, anti-inflammatory agents, and pro-angiogenesis agents.

Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte-activating moiety.

Methods for applying a coating to a surface of a substrate for inhibition and prevention of implant-associated complications (including implant-associated infections), methods for inhibiting and preventing implant-associated complications (including implant-associated infections), implant-associated infection inhibiting coatings, and coated devices are provided. Coating processes include a) providing a saturated or supersaturated solution of an antibiotic in a fast-evaporating or medium-evaporating organic solvent; b) coating the surface of the substrate with at least one application of solution, each application followed directly by a solvent evaporation period.

The present invention provides a hemostatic porous composite sponge comprising: i) a matrix of a biomaterial; and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that said polymeric component is coated onto a surface of said matrix of a biomaterial, or said matrix is impregnated with said polymeric material, or both.

A polymeric medical device/implant coating is disclosed for the delivery of drugs or therapeutic compounds such as antibiotics over an extended period of time and at levels or concentrations that exceed the MIC. In one embodiment, an antibiotic such as vancomycin is encapsulated in a photo-crosslinked poly(lactide-co-glycolide) (PLGA)-dimethacrylate coating. The drug release profile of this coating was studied and the initial burst was reduced by photo-crosslinking. Due to photo-crosslinking, an additional diffusional resistance was created, which prevented easy diffusion of the drug into the release medium. Moreover, the time required for this coating process is very quick (e.g., around 5 minutes) and makes it compatible for this coating to be applied in the operating room.

Provided herein are compositions including polymeric binder or a salt thereof, high molecular weight polymer, pharmaceutically active agent and a low molecular weight cross-linking agent, methods for using the compositions to coat a substrate, and methods for making the compositions. Alternatively, the composition may include a polymeric binder or a salt thereof, high molecular weight polymer and a pharmaceutically active agent. In particular, the substrate may form part of an apparatus on which it would be beneficial to limit biofouling and/or protein binding.

Powdered collagen compositions and methods for wound care or the dressing or treatment of wounds in a subject in need thereof. The powdered collagen wound care composition includes powdered collagen or collagen-based material substantially covered with a hydrophobic barrier. In at least some instances, the hydrophobic barrier prevents the complete absorption or dissolution of the powdered collage or collagen-based material when placed on or in a wound or body of a subject for at least three (3) days. The powdered collagen wound care compositions are suitable for dressing or packing wounds or post-surgical incisions.

Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, trans-differentiation, and proliferation of animal cells into the osteoblast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

A method of incorporating silver and/or copper into a biomedical implant includes: providing an implant having an outer surface; depositing silver and/or copper onto the outer surface of the implant; diffusing the silver and/or copper into a subsurface zone adjacent the outer surface; and oxidizing or anodizing the implant after the diffusion step to form an oxidized or anodized layer that contains at least some amount of elemental silver, elemental copper or silver or copper ions or compounds.

A medical polymer device comprising a biodegradable polymer is provided, wherein the biodegradable polymer has a crystallinity of about 10% to about 80%, and preferably from about 20% to about 60%, wherein the medical polymer device comprises a small molecule organic compound which diffuses into the biodegradable polymer, the small molecule organic compound has a molecular weight of from about 100 to about 1000 Daltons, preferably from about 150 to about 500 Daltons, and more preferably from about 150 to about 250 Daltons, and the small molecule organic compound is non-evaporating or low-evaporating. The present invention also provides a method for preparing a medical polymer device according to the present invention as well as a method for modifying a medical polymer device made from a biodegradable polymer.